Feasibility Study on Adjuvant Carboplatin and S-1 in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer

Trial Profile

Feasibility Study on Adjuvant Carboplatin and S-1 in patients with completely resected stage II-IIIA Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2014

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Dec 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 14 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top